Table 3.
Univariate analysis for disease-free survival (DFS) and overall survival (OS)
| Gene | Genotype | Disease-free survival |
Overall Survival |
||||||
|---|---|---|---|---|---|---|---|---|---|
| N | NR | HRR (95% CI) | p-value (PTrend) | N | ND | HRD (95% CI) | p-value (PTrend) | ||
| IL10-1082 | GG | 104 | 27 | 1.00 | 0.77 (0.57) | 118 | 32 | 1.00 | 0.99 (0.91) |
| GA | 166 | 43 | 0.99 (0.62–1.6) | 191 | 53 | 1.03 (0.67–1.59) | |||
| AAlow expressor | 100 | 29 | 1.17 (0.69–2.0) | 116 | 32 | 1.03 (0.63–1.68) | |||
| IL10-819 | CC | 236 | 66 | 1.00 | 0.66 (0.57) | 267 | 74 | 1.00 | 0.71 (0.41) |
| CT | 96 | 28 | 1.01 (0.65–1.6) | 109 | 34 | 1.12 (0.75–1.68) | |||
| TTlow expressor | 17 | 3 | 0.59 (0.18–2.0) | 21 | 7 | 1.34 (0.60–3.01) | |||
| IL10-592 | CC | 258 | 68 | 1.00 | 0.89 (0.88) | 287 | 77 | 1.00 | 0.64 (0.33) |
| CA | 100 | 28 | 1.03 (0.66–1.6) | 118 | 37 | 1.18 (0.80–1.75) | |||
| AAlow expressor | 12 | 2 | 0.72 (0.16–3.2) | 13 | 4 | 1.39 (0.47–4.11) | |||
| IL-10R-109 | GG | 124 | 34 | 1.00 | 0.64 (0.86) | 145 | 48 | 1.00 | 0.14 (0.35) |
| GA | 142 | 35 | 0.86 (0.54–1.4) | 161 | 37 | 0.65 (0.43–1.00) | |||
| AA | 69 | 22 | 1.09 (0.65–1.8) | 74 | 23 | 0.86 (0.53–1.41) | |||
| TGFβ1 896 | TT | 144 | 43 | 1.00 | 0.45 (0.91) | 163 | 41 | 1.00 | 0.31 (0.12) |
| TC | 174 | 43 | 0.84 (0.56–1.3) | 204 | 61 | 1.29 (0.87–1.92) | |||
| CChigh expressor | 33 | 12 | 1.26 (0.66–2.4) | 35 | 13 | 1.49 (0.81–2.74) | |||
| TGFβR1 195 | AA | 235 | 61 | 1.00 | 0.49 (0.3) | 263 | 71 | 1.00 | 0.07 (0.07) |
| AG | 116 | 33 | 1.15 (0.75–1.8) | 133 | 39 | 1.16 (0.78–1.72) | |||
| GG | 11 | 4 | 1.77 (0.61–5.2) | 16 | 8 | 2.45 (1.16–5.17) | |||
| VEGF-2578 | AA | 76 | 18 | 1.00 | 0.12 (0.1) | 85 | 21 | 1.00 | 0.08 (0.06) |
| AC | 153 | 36 | 0.97 (0.55–1.7) | 176 | 45 | 1.02 (0.61–1.70) | |||
| CChigh expressor | 115 | 40 | 1.51 (0.87–2.6) | 135 | 48 | 1.56 (0.94–2.59) | |||
| VEGF-1154 | AA | 22 | 7 | 1.00 | 0.43 (0.76) | 24 | 7 | 1.00 | 0.16 (0.18) |
| AG | 138 | 33 | 0.64 (0.28–1.5) | 152 | 37 | 0.75 (0.33–1.70) | |||
| GGhigh expressor | 161 | 48 | 0.81 (0.36–1.8) | 187 | 62 | 1.10 (0.50–2.45) | |||
| VEGF-634 | GG | 146 | 42 | 1.00 | 0.53 (0.68) | 164 | 48 | 1.00 | 0.73 (0.88) |
| GC | 164 | 40 | 0.79 (0.51–1.2) | 189 | 50 | 0.88 (0.59–1.30) | |||
| CChigh expressor | 48 | 15 | 0.99 (0.56–1.7) | 54 | 17 | 1.04 (0.60–1.78) | |||
| VEGFR+889 | GG | 277 | 84 | 1.00 | 0.02 (0.07) | 310 | 93 | 1.00 | 0.44 (0.34) |
| GA | 68 | 9 | 0.40 (0.20–0.8) | 81 | 18 | 0.72 (0.43–1.20) | |||
| AA | 5 | 2 | 1.44 (0.33–6.3) | 5 | 2 | 1.18 (0.35–3.96) | |||
| VEGFR+1416 | TT | 244 | 72 | 1.00 | 0.15 (0.23) | 277 | 82 | 1.00 | 0.37 (0.61) |
| TA | 108 | 21 | 0.63 (0.39–1.0) | 121 | 28 | 0.77 (0.50–1.18) | |||
| AA | 15 | 5 | 1.09 (0.48–2.5) | 17 | 6 | 1.27 (0.56–2.86) | |||
| VEGFR IVS25-92 | GG | 191 | 46 | 1.00 | 0.19 (0.06) | 219 | 59 | 1.00 | 0.45 (0.3) |
| GA | 112 | 35 | 1.37 (0.89–2.1) | 127 | 42 | 1.29 (0.87–1.91) | |||
| AA | 30 | 11 | 1.67 (0.86–3.3) | 32 | 10 | 1.16 (0.60–2.24) | |||
| VEGFR IVS6+54 | AA | 118 | 38 | 1.00 | 0.38 (0.19) | 133 | 45 | 1.00 | 0.28 (0.34) |
| AG | 151 | 38 | 0.77 (0.49–1.2) | 167 | 41 | 0.71 (0.47–1.09) | |||
| GG | 72 | 18 | 0.71 (0.41–1.2) | 85 | 25 | 0.83 (0.51–1.33) | |||
NR number recurrent, ND number died, HRR hazard ratio for disease recurrence, HRD hazard ratio for disease-related mortality